MPM
MYGN icon

Meritage Portfolio Management’s Myriad Genetics MYGN Stock Holding History

Meritage Portfolio Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-168,189
Closed -$3.46M – 195
2016
Q3 		$3.46M Buy
+168,189
New +$4.27M 0.38% 133
2013
Q4 		– Sell
-85,507
Closed -$2.01M – 205
2013
Q3 		$2.01M Buy
85,507
+587
+0.7% +$16.7K 0.26% 165
2013
Q2 		$2.28M Buy
+84,920
New +$2.46M 0.33% 148

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Meritage Portfolio Management's MYGN Position: Q4 2016 in Review

Meritage Portfolio Management sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 168,189 shares — an estimated $3.46M sold.

Meritage Portfolio Management first reported a position in MYGN in Q2 2013 and held it in 3 quarters. The position peaked at $3.46M in Q3 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

  • Meritage Portfolio Management reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
  • Meritage Portfolio Management sold 168,189 Myriad Genetics shares in Q4 2016, an estimated $3.46M.
  • Meritage Portfolio Management first reported a position in Myriad Genetics in Q2 2013 and held it in 3 quarters.
  • Meritage Portfolio Management's Myriad Genetics position peaked at $3.46M in Q3 2016.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Meritage Portfolio Management's 13F filing for Q4 2016, filed 24 Jan 2017.